Skip to main content
. 2023 Nov 22;40(12):1143–1155. doi: 10.1007/s40266-023-01077-7

Table 1.

Characteristics of the total population (N = 285), non-long stayers (n = 222), and long stayers (n = 63)

Total population (n = 285) Non-long stayers
< 14 days (n = 222)
Long stayers
≥ 14 days (n = 63)
Intervention group (N = 148) Control group (N = 137) Intervention group (n = 106) Control group (n = 116) Intervention group (n = 42) Control group (n = 21)
Age included, years mean (SD) 82.8 (6.0) 82.1 (5.9) 82.4 (6.1) 81.9 (5.9) 83.9 (5.9) 82.9 (6.1)
Sex, n (%)a
 Female 98 (66.2) 74 (54.0) 69 (65.1) 65 (56.0) 29 (69.1) 9 (42.9)
Level of education, n (%)a
 Low (≤12 years) 75 (52.8) 73 (54.1) 52 (49.1) 64 (55.2) 23 (54.8) 9 (42.9)
 High (>12 years) 67 (47.2) 62 (45.9) 50 (47.2) 50 (43.1) 17 (40.5) 12 (57.1)
 Missing 6 (4.1) 2 (1.5) 4 (3.8) 2 (1.7) 2 (4.8) 0 (0)
Living status at admission, n (%)a
 Home dwelling 137 (92.6) 129 (94.2) 100 (94.3) 111 (95.7) 37 (88.1) 18 (85.7)
 Living alone 86 (58.5) 82 (59.9) 59 (56.2) 69 (59.5) 27 (64.3) 13 (61.9)
Need for assistance, n (%)a
 Home care services 75 (50.7) 77 (56.2) 48 (45.3) 63 (54.3) 27 (61.3) 14 (66.7)
 Multi-dose adherence aid 43 (29.0) 48 (35.0) 27 (25.5) 38 (32.8) 16 (38.1) 10 (47.6)
 Handling own medications 77 (52.0) 64 (46.7) 59 (55.7) 58 (50.0) 18 (42.9) 6 (28.6)
Medication use, mean (SD)
 Number of medications regular use 6.6 (4.0) 7.4 (4.0) 6.8 (4.1) 7.2 (4.0) 6.4 (3.9) 8.5 (3.9)
 Number of medications total 8.7 (5.1) 9.6 (5.4) 8.8 (5.1) 9.4 (5.4) 8.5 (5.1) 10.5 (5.1)
Comorbidities in admission notes, n (%)a
 Hypertension 75 (51.0) 69 (50.4) 54 (50.4) 58 (50.0) 21 (50.0) 11 (52.4)
 Asthma or COPD 44 (29.7) 38 (27.7) 34 (32.1) 33 (28.5) 10 (23.8) 5 (23.8)
 Atrial fibrillation 37 (25.0) 42 (30.7) 15 (23.6) 36 (31.0) 12 (28.6) 6 28.6)
 Diabetes mellitus 28 (18.9) 31 (22.6) 21 (19.8) 25 (21.6) 7 (16.7) 6 (28.6)
 Heart failure 24 (16.2) 21 (15.3) 14 (13.2) 17 (14.7) 10 (23.8) 4 (19.1)
 Renal failure 24 (16.2) 21 (15.3) 14 (13.2) 16 (13.8) 10 (23.8) 5 (23.8)
 Anxiety/depression 17 (11.5) 11 (8.0) 11 (10.4) 10 (8.6) 6 (13.3) 1 (4.8)
 Dementia 7 (4.7) 4 (2.9) 3 (2.8) 4 (3.5) 4 (9.5) 0 (0)
Study ward, n (%)a
 Ward 1 117 (79.1) 103 (75.2) 80 (75.5) 85 (73.3) 37 (88.1) 18 (85.7)
 Ward 2 31 (21.0) 34 (24.8) 26 (24.5) 31 (26.7) 5 (11.9) 3 (14.3)
Died during the study period, n (%)a 14 (9.5) 12 (8.8) 7 (6.6) 10 (8.6) 7 (16.7) 2 (9.5)
EQ-5D utility score at dischargeb 0.510 0.472 0.512 0.491 0.507 0.366
EQ-5D utility score at 1 month follow-upb 0.522 0.500 0.568 0.530 0.398 0.328
EQ-5D utility score at 6 months follow-upb 0.507 0.454 0.566 0.454 0.346 0.456
EQ-5D utility score at 12 months follow-upb 0.441 0.429 0.508 0.441 0.245 0.359
Patients with prolonged hospitalizations (index or readmissions) ≥14 days, n (%)a 42 (28.3) 21 (15.3) N/A N/A N/A N/A
Total healthcare costs in previous year, € mean (95% CI)c 11,085 (8535–13,922) 11,975 (8835–15,249) 8409 (6081–11,159) 12,226 (8813–16,726) 17,840 (11,721–23,959) 10,586 (5794–16,807)

CI confidence interval, COPD chronic obstructive pulmonary disease, N/A not applicable, SD standard deviation

aPercentages were rounded

bAdjusted for common fixed baseline of 0.487

cCIs were bias corrected using bootstrap